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Objectives The aim of this study was to assess the degree of platelet inhibition by adjunctive
cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450
2C19 (CYP2C19) genotype.
Background Although adjunctive cilostazol intensiﬁes platelet inhibition in AMI patients, it is
not established whether this regimen can be free from the effect of CYP2C19 loss-of-function
variants (*2/*3).
Methods We randomly assigned 126 AMI patients with available CYP2C19 genotyping to receive
adjunctive cilostazol (triple group; n  64) or high maintenance-dose (MD) clopidogrel of 150 mg/
day (high-MD group; n  62). Using conventional aggregometry and VerifyNow (Accumetrics Inc.,
San Diego, California), platelet reactivity was measured at pre-discharge and 30-day follow-up. Pri-
mary endpoint was change in maximal platelet aggregation (∆Aggmax) between pre-discharge and
30-day follow-up. High on-treatment platelet reactivity (HPR) was deﬁned as 20 mol/l adenosine
diphosphate–induced maximal platelet aggregation (Aggmax) 59%.
Results In noncarriers, despite numerically greater inhibition by adjunctive cilostazol, changes
in platelet measures and the rate of HPR did not signiﬁcantly differ between the 2 groups. In
carriers, ∆Aggmax after 5 and 20 mol/l adenosine diphosphate stimuli was signiﬁcantly higher
in the triple (n  39) versus high-MD group (n  38) (21.8  13.9% vs. 9.0  13.3%, p  0.001,
nd 24.2  17.2% vs. 7.7  15.5%, p  0.001, respectively). Likewise, changes in late platelet
ggregation and P2Y12 reaction unit were consistently greater in the triple versus high-MD
roup. Fewer patients in the triple group met the criteria of HPR at 30-day follow-up than in
he high-MD group (15.4% vs. 44.7%, p  0.005).
onclusions Compared with high-MD clopidogrel, adjunctive cilostazol signiﬁcantly enhances platelet
nhibition and reduces the rate of HPR, especially in AMI patients with CYP2C19 loss-of-function variants.
Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Acute Myocardial Infarction (AMI)
atients According to CYP2C19 Polymorphism [ACCELAMI2C19]; NCT00915733) (J Am Coll Cardiol Intv
011;4:381–91) © 2011 by the American College of Cardiology Foundation
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382Atherosclerotic plaque rupture or erosion and its down-
stream activation of platelet aggregation are the main causes
of acute myocardial infarction (AMI). Adequate platelet
inhibition by antiplatelet therapy is a crucial strategy for
AMI management, and high on-treatment platelet reactiv-
ity (HPR) after standard antiplatelet therapy is significantly
associated with the risk of recurrent cardiovascular events in
See page 411
AMI patients (1,2). Although the mechanisms of wide inter-
individual variability in response to clopidogrel are multifacto-
rial, carriage of the hepatic cyto-
chrome P450 2C19 (CYP2C19)
loss-of-function (LOF) alleles has
shown a most important influence
on decreased response to clopi-
dogrel and consequent risk of
ischemic events in AMI patients
undergoing percutaneous coro-
nary intervention (PCI) (3–5).
Adjunctive cilostazol, a selec-
tive phosphodiesterase type 3 in-
hibitor, to standard antiplatelet
therapy (so-called triple anti-
platelet therapy) enhances inhi-
bition of adenosine diphosphate
(ADP)-induced platelet aggre-
gation than high maintenance-
dose (MD) clopidogrel of 150
mg daily (6) and reduces long-
term clinical events in AMI pa-
tients (7,8). Although accumu-
lating data have shown clinical
benefits of triple antiplatelet
therapy on post-PCI ischemic
events (7–10), most studies in-
cluded East Asian populations.
Because it is difficult to general-
ize the benefit of triple antiplate-
let therapy across the ethnicity,
platelet function testing and
pharmacogenetic analysis are now required to reveal the
ground rules.
Interestingly, the common polymorphism of the
CYP2C19 gene (*2/*3) is more prominently present
among East Asians than whites (60% vs. 30%) (3–5).
In addition, because cilostazol is converted mainly into
Corporation, Seoul, Korea. Dr. Jeong has received honoraria for lectures from Sanofi-
Aventis, Daiichi Sankyo Inc., and Otsuka. The other authors have reported that they have
no relationships to disclose.
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
Agglate  late platelet
aggregation at 5 min
Aggmax  maximal platelet
aggregation
AMI  acute myocardial
infarction
BASE  baseline value
CYP2C19  the hepatic
cytochrome P450 2C19
HPR  high on-treatment
platelet reactivity
LD  loading-dose
LOF  loss-of-function
LTA  light transmittance
aggregometry
MD  maintenance-dose
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
PRU  P2Y12 reaction unit
STEMI  ST-segment
elevation myocardial
infarctionManuscript received August 14, 2010; revised manuscript received December 13,
2010, accepted December 26, 2010.the active metabolites by the CYP3A system (11), platelet
inhibition by adjunctive cilostazol is expected to be influ-
enced to a lesser extent or not at all by the CYP2C19 LOF
variant carriage. Although adjunctive cilostazol can be an
alternative regimen to overcome the risk of HPR in carriers
of the CYP2C19 variants, it has not been yet demonstrated.
The aim of this study was to assess the degree of enhanced
platelet inhibition by adjunctive cilostazol in AMI patients
according to CYP2C19 genotype, compared with another
intensified antiplatelet therapy, high-MD clopidogrel.
Methods
Patient selection. We enrolled the study cohort from con-
ecutive AMI patients admitted to Gyeongsang National
niversity Hospital between October 2007 and June 2009.
atients were eligible for this study if they were admitted for
MI, 18 years of age, and treated with uneventful PCI.
s previously described (6), we defined AMI as clinical
ymptoms compatible with acute myocardial ischemia
ithin 12 h before admission with a subsequently docu-
ented increase in cardiac troponin levels. ST-segment
levation myocardial infarction (STEMI) was pre-specified
s ST-segment elevation 1 mm in at least 2 contiguous
eads in the admission electrocardiogram or left bundle-
ranch block, and all STEMI patients were treated with
rimary PCI 12 h after the onset of pain. The remaining
MI patients with no such electrocardiogram changes
onstituted the non–ST-segment elevation myocardial in-
arction (NSTEMI) cohort, and all NSTEMI patients
nderwent PCI within 48 h after admission. Major exclusion
riteria included a history of active bleeding and bleeding
iatheses, oral anticoagulation therapy with Coumadin, left
entricular ejection fraction 30%, leukocyte count 3,000/
m3 and/or platelet count 100,000/mm3, aspartate ami-
notransferase or alanine aminotransferase level 3 the
upper normal limits, serum creatinine level 2.5 mg/dl, or
noncardiac disease with a life expectancy 1 year. The
present study protocol complies with the Declaration of
Helsinki and was approved by the Institutional Ethics
Committee of Gyeongsang National University Hospital.
All patients provided written informed consent for deoxy-
ribonucleic acid (DNA) genotyping and for the participa-
tion in the study.
Study design. This ACCELAMI2C19 (Adjunctive Cilosta-
zol Versus High Maintenance-Dose Clopidogrel in Acute
Myocardial Infarction [AMI] Patients According to CYP2C19
Polymorphism) study was the expanded study of a prospective,
randomized, parallel-group platelet function trial (ACCEL-
AMI [Adjunctive Cilostazol Versus High Maintenance-Dose
Clopidogrel in Patients With AMI] study) (6). The flow
diagram is illustrated in Figure 1. Immediately after admission
to the hospital, all patients received a 600-mg loading-dose
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383(LD) of clopidogrel, followed by an MD of 75 mg daily before
randomization. All patients also took a 300-mg LD of aspirin,
followed by aspirin 200 mg daily throughout the study period.
Use of low-molecular-weight heparin (enoxaparin) or unfrac-
tionated heparin was at the physician’s discretion, and only
tirofiban with a short half-life was administered if needed.
Pre-discharge platelet reactivity was measured either at least 3
days after PCI in patients not treated with tirofiban or at 5
days after procedure in patients treated with tirofiban. Inter-
ventional procedures were performed according to standard
techniques. After blood sampling, the patients were randomly
assigned to high-MD clopidogrel of 150 mg daily (high-MD
group) or adjunctive cilostazol 100 mg twice daily to clopi-
dogrel 75 mg daily (triple group) using a computer-generated
randomization table. At 30-day follow-up, patient compliance
to antiplatelet therapy was assessed by interview, pill counting,
and a survey. If patients showed complete compliance, periph-
eral venous blood was drawn from an antecubital vein within 2
to 4 h after the last intake. Of 140 AMI cohorts, CYP2C19
genotype could be determined in 126 patients (88.6%), who
constituted the study subjects.
CYP2C19 genotype. Genomic DNA was extracted from leu-
ocytes of whole-blood specimens with an extraction kit
QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany).
ecause the allelic frequencies of the CYP2C19*4 to *6 are
xtremely rare in East Asians (12,13), genotyping for
YP2C19*2 (rs4244285, c.681GA) and CYP2C19*3
rs4986893, c.636GA) were conducted with a single base
rimer extension assay using the SNaPshot assay kit (Applied
iosystems, Foster City, California) (3). Briefly, the genomic
NA region containing 1 of the 2 alleles was amplified with
Figure 1. Flow Diagram of the ACCELAMICYP2C19 Study
The diagram shows process of the ACCELAMICYP2C19 (Adjunctive Cilosta-
zol Versus High Maintenance-Dose Clopidogrel in Acute Myocardial Infarc-
tion [AMI] Patients According to CYP2C19 Polymorphism) study. CYP  the
hepatic cytochrome P450; DNA  deoxyribonucleic acid.olymerase chain reaction separately. Polymerase chain reac-ion was carried out using the same primers as previously
escribed. The polymerase chain reaction product was pro-
essed as per the ABI SNaPshot protocol, using primers
esigned for fluorescent dideoxy nucleotide termination. Single
ucleotide polymorphism analysis was carried out on the ABI
100 genetic analyzer (Applied Biosystems).
Platelet function assays. Blood samples were collected using
he double-syringe technique, in which the first 2 to 4 ml of
lood were discarded to avoid spontaneous platelet activa-
ion. Platelet reactivity was simultaneously measured by light
ransmittance aggregometry (LTA) and the VerifyNow P2Y12
assay (Accumetrics Inc., San Diego, California). Correla-
tion between LTA and the VerifyNow P2Y12 assay at our
aboratory has been previously reported (14).
We performed LTA according to standard protocol,
hich has been described in detail elsewhere (6). Blood
amples were drawn into Vacutainer tubes containing 0.5 ml
f 3.2% sodium citrate (Becton-Dickinson, San Jose, Cali-
ornia) and processed within 2 h. Platelet-rich plasma was
btained as a supernatant fluid after centrifuging the blood
t 120 g for 10 min. The remaining blood was further
entrifuged at 1,200 g for 10 min to prepare platelet-poor
lasma. Platelet-rich plasma was adjusted to platelet counts
f 250,000/mm3 by adding platelet-poor plasma as needed.
Platelet aggregation was assessed at 37°C using an AggRAM
aggregometer (Helena Laboratories Corp., Beaumont,
Texas). Light transmission was adjusted to 0% with
platelet-rich plasma and to 100% with platelet-poor plasma
for each measurement. Platelet function tests were per-
formed after the addition of 5 and 20 mol/l ADP, and the
curves were recorded for 10 min. Platelet reactivity was
determined at maximal aggregation (Aggmax) and late ag-
gregation at 5 min (Agglate). Absolute change in platelet
ggregation (Aggmax and Agglate) was defined as change
n values between the pre-discharge and 30-day follow-up
ime points: Agg  (pre-discharge platelet aggregation —
latelet aggregation at 30-day follow-up).
The VerifyNow P2Y12 assay is a whole-blood, point-of-
are system that has been developed to assess responsiveness
o P2Y12 antagonists (15). Blood was drawn into a Greiner
Bio-One 3.2% citrate Vacuette tube (Greiner Bio-One,
Kremsmünster, Austria). The assay device consists of 2
whole-blood assay channels. One contains fibrinogen-coated
polystyrene beads and 20 mol/l ADP, which also contains
22 nmol/l prostaglandin E1 to reduce nonspecific contribu-
tion of other pathways. The other separate channel contains
fibrinogen-coated polystyrene beads and isothrombin recep-
tor activating protein. Platelet aggregation by the isothrom-
bin receptor activating protein can occur independently of
the P2Y12 receptors, and a baseline value (BASE) for
platelet function is obtained. The results are reported in
P2Y12 reaction unit (PRU), BASE, and percentage of
inhibition. The percentage of inhibition is calculated as:
([BASE – PRU]/BASE)  100. Absolute changes in PRU
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384(PRU) were defined as changes of values between pre-
discharge and 30-day follow-up time points: PRU 
(pre-discharge PRU – PRU at 30-day follow-up).
Endpoints and deﬁnitions. The primary endpoint was
Aggmax according to CYP2C19 phenotype. The secondary
ndpoints included Agglate, PRU, and the rate of HPR
t 30-day follow-up according to CYP2C19 phenotype. In
ddition, we assessed the composite rates of death, nonfatal
MI, and urgent target-vessel revascularization at 30-day
ollow-up. Bleeding was defined according to the criteria
sed in the TIMI (Thrombolysis In Myocardial Infarction)
rials. The cutoff point of HPR was defined as 20 mol/l
DP-induced Aggmax 59% in the basis of a consensus
opinion of the Working Group on High On-Treatment
Platelet Reactivity (16,17). According to DNA phenotype,
enrolled patients were classified into carriers versus noncar-
riers of the CYP2C19*2/*3 LOF alleles.
Sample size calculation and statistical analysis. The sample
ize calculation was based on the results of the ACCEL-
MI study (6). In terms of 20 mol/l ADP-induced
Aggmax, adjunctive cilostazol could achieve a greater value
when compared with the doubling dose of clopidogrel
(29.8% vs. 8.1%). To reveal such a 21.7% absolute difference
in 20 mol/l ADP-induced Aggmax between the groups,
t least 22 patients per group would be required to provide
n 80% power to detect a statistical difference with a 2-sided
lpha value of 0.05 and SD of 25%. The East Asian
opulation shows close to a 60% rate of the CYP2C19
ariant carriage (3); the needed study population for each
reatment group was at least 55 patients including 22
oncarriers and 33 carriers of the CYP2C19 LOF allele.
ontinuous variables are expressed as mean SD, and their
ifferences were tested using the Student unpaired t or
ann-Whitney U tests. Categorical variables are expressed
s frequencies and percentages, and chi-square statistics or
isher exact test was used for their comparisons. If some
ariable showed a significant difference between groups,
egression analysis for adjusting was performed including
latelet measures. We calculated Hardy-Weinberg equilib-
ium using the Pearson goodness-of-fit chi-square statistics
o test a possible deviation with regard to distribution of
YP2C19 genotype. A p value 0.05 was considered statisti-
ally significant, and statistical analysis was performed using
PSS software (version 13.0, SPSS Inc., Chicago, Illinois).
esults
Patient characteristics and clinical follow-up. One hundred
twenty-six subjects were enrolled in this study (62 patients
in the high-MD group and 64 patients in the triple group)
(Fig. 1). During the study period, no major cardiovascular or
bleeding events were noted in any group. One patient in the
triple group suffered from TIMI minor bleeding caused by
entry site aneurysm and hematoma. Although there was 1patient with considerable headache and 1 patient with palpi-
tation during the early phase of triple antiplatelet therapy, all
patients tolerated therapy well and did not discontinue the
study regimens. Distributions of CYP2C19 genotype did not
differ from that published for East Asians (17,18) and did not
deviate from Hardy-Weinberg equilibrium (CYP2C19*2;
p  0.85, and CYP2C19*3; p  0.33, respectively). Similar
to previous studies (3,18), prevalence of the CYP2C19*2/*3
LOF alleles was relatively high (61.1%) (Table 1). There
were no differences in pre-discharge and 30-day follow-up
platelet measures between carriage of the CYP2C19*2 versus
*3 variant (data not shown). In addition, pre-discharge
platelet measures did not differ according to time interval
between PCI and platelet function assay (Online Table).
There were no statistically significant differences in clopi-
dogrel loading to first platelet function assay, and clinical
and procedural characteristics between the treatment groups
according to CYP2C19 genotype, except for younger age in
the high-MD versus triple group with the CYP2C19 variant
(Table 2). In addition, adjusting statistically for age did not
alter any of the endpoints based on platelet function assays.
Platelet measures in STEMI versus NSTEMI patients did
not differ at pre-discharge and 30-day follow-up (data not
shown).
Platelet reactivity by LTA. Pre-discharge values of LTA
were similar between the treatment groups regardless of
CYP2C19 genotype (Table 3). Thirty-day follow-up values
of LTA did not differ between both treatments in noncar-
riers, whereas the triple group in carriers showed lower
platelet measures at 30-day follow-up than the high-MD
group. In noncarriers, Aggmax in the triple group seemed
umerically greater than that in the high-MD group, but
id not reach the significant difference: 5 mol/l and 20
mol/l ADP-stimulated values (18.8%  12.5% vs. 12.3% 
13.8%, p  0.094, and 20.9%  13.9% vs. 15.5%  15.1%,
 0.197, respectively) (Fig. 2A). In carriers, Aggmax was
greater after triple antiplatelet therapy compared with
high-MD clopidogrel: Aggmax with 5 mol/l ADP stim-
Table 1. Distributions of the CYP2C19 Genotypes in the
High-MD and Triple Groups
Genotype Metabolism Activity
Total
Cohort
(n  126)
High-MD
Group
(n  62)
Triple
Group
(n  64)
*1/*1 Extensive metabolizer 49 (38.9%) 24 (38.7%) 25 (39.1%)
*1/*2 Intermediate metabolizer 46 (36.5%) 22 (35.5%) 24 (37.5%)
*1/*3 Intermediate metabolizer 12 (9.5%) 6 (9.7%) 6 (9.4%)
*2/*2 Poor metabolizer 11 (8.7%) 6 (9.7%) 5 (7.8%)
*2/*3 Poor metabolizer 8 (6.4%) 4 (6.4%) 4 (6.2%)
*3/*3 Poor metabolizer 0 (0%) 0 (0%) 0 (0%)
Values are n (%).CYP the hepatic cytochrome P450; MDmaintenance-dose.
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385Table 2. Baseline Clinical and Procedural Characteristics According to CYP2C19 Variant Carriage
Noncarriers Carriers
Variables High-MD Group (n  24) Triple Group (n  25) p Value High-MD Group (n  38) Triple Group (n  39) p Value
Demographic characteristics
Age, yrs 63.4 10.6 61.0 15.0 0.527 56.8 12.5 65.8 9.0 0.001
Male 16 (66.7) 18 (72.0) 0.686 27 (71.1) 31 (79.5) 0.391
Body mass index, kg/m2 24.5 3.0 24.3 2.8 0.834 24.8 3.0 23.9 2.0 0.133
Clinical presentation 0.195 0.906
STEMI 15 (62.5) 11 (44.0) 20 (52.6) 20 (51.3)
NSTEMI 9 (37.5) 14 (56.0) 18 (47.4) 19 (48.7)
Clinical characteristics
Diabetes mellitus 7 (29.2) 6 (24.0) 0.682 8 (21.1) 14 (35.9) 0.149
Hypertension 12 (50.0) 12 (48.0) 0.889 16 (42.1) 19 (48.7) 0.560
Hypercholesterolemia 5 (20.8) 3 (12.0) 0.463 11 (28.9) 16 (41.0) 0.267
Current smoking 12 (50.0) 14 (56.0) 0.674 27 (71.1) 22 (56.4) 0.182
Chronic kidney disease 4 (16.7) 6 (24.0) 0.725 5 (13.2) 5 (12.8) 1.000
History
Previous PCI 1 (4.2) 0 (0) 0.490 1 (2.6) 3 (7.7) 0.615
Previous myocardial infarction 1 (4.2) 1 (4.0) 1.000 3 (7.9) 2 (5.1) 0.675
Previous bypass surgery 0 (0) 0 (0) 1.000 0 (0) 2 (5.1) 0.494
Previous stroke 1 (4.2) 0 (0.0) 0.490 0 (0) 0 (0) 1.000
Concomitant medications
Statin 24 (100.0) 24 (96.0) 1.000 36 (94.7) 39 (100.0) 0.240
CYP3A4 metabolized 18 (75.0) 17 (68.0) 0.588 28 (73.7) 32 (82.1) 0.376
Beta blocker 20 (83.3) 21 (84.0) 1.000 37 (97.4) 36 (92.3) 0.615
Angiotensin receptor blocker 24 (100.0) 24 (96.0) 1.000 37 (97.4) 36 (92.3) 0.615
Nitrate 15 (62.5) 15 (60.0) 0.858 28 (73.7) 26 (66.7) 0.501
Calcium channel blocker 2 (8.3) 3 (12.0) 1.000 4 (10.5) 3 (7.7) 0.711
Proton pump inhibitor 0 (0) 0 (0) 1.000 0 (0) 1 (2.6) 1.000
Laboratory characteristics
LV ejection fraction 45% 5 (20.8) 8 (32.0) 0.376 7 (18.4) 3 (7.7) 0.192
Hemoglobin, g/dl 13.7 1.4 13.9 1.9 0.739 14.1 1.7 13.6 1.2 0.125
Platelet count, 103/mm3 297 67 264 101 0.189 274 59 279 73 0.707
Hb A1C, % 6.2 (5.7–6.9) 5.9 (5.6–6.8) 0.732 6.1 (5.7–7.1) 6.0 (5.3–6.7) 0.554
GFR (MDRD, ml/min/1.73 m2) 81.9 20.9 76.8 29.1 0.489 86.5 26.1 81.5 21.7 0.360
Total cholesterol, mg/dl 204.6 62.0 178.5 37.8 0.080 195.2 39.7 184.1 48.5 0.277
Lesion and procedural characteristics
Infarct-related artery 0.772 0.304
Left anterior descending 13 (54.2) 14 (56.0) 20 (52.6) 15 (38.5)
Left circumﬂex 5 (20.8) 6 (24.0) 8 (21.1) 8 (20.4)
Right coronary 6 (25.0) 5 (20.0) 10 (26.3) 15 (38.5)
Left main 0 (0) 0 (0) 0 (0) 1 (2.6)
Multivessel disease 10 (41.7) 13 (52.0) 0.469 20 (52.6) 22 (56.4) 0.739
Aspiration thrombectomy 3 (12.5) 6 (24.0) 0.463 7 (18.4) 9 (23.1) 0.615
Administration of GPI 1 (0.5) 0 (0) 0.490 3 (7.9) 1 (2.6) 0.358
Intravascular ultrasound guidance 16 (66.7) 19 (76.0) 0.470 23 (60.5) 26 (66.7) 0.575
Multivessel intervention 5 (20.8) 3 (12.0) 0.463 11 (28.9) 10 (25.6) 0.745
Intervention method 0.580 0.150
Drug-eluting stent 23 (95.8) 23 (92.0) 35 (92.1) 38 (97.4)
Bare-metal stent 0 (0) 0 (0) 0 (0) 1 (2.6)
Ballooning only 1 (4.2) 2 (8.0) 3 (7.9) 0 (0)
Stents per patient, n 1 (1–2) 2 (1–2) 0.872 2 (1–3) 1 (1–2) 0.100
Total stent length, mm 30 (23–51) 42 (28–56) 0.986 38 (24–55) 38 (28–64) 0.308
Values are mean SD, n (%), or median (interquartile range).
GFR glomerular filtration rate; GPI glycoprotein IIb/IIIa inhibitor; Hb A1C hemoglobin A1C; LV left ventricular; MDRDModification of Diet in Renal Disease; NSTEMI non–ST-segment elevationmyocardial infarction; PCI percutaneous coronary intervention; STEMI ST-segment elevation myocardial infarction; other abbreviations as in Table 1.
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386ulus was 21.8  13.9% versus 9.0  13.3% (p  0.001),
hereas it was 24.2  17.2% versus 7.7  15.5% with 20
mol/l ADP stimuli, respectively (p  0.001) (Fig. 2B).
For noncarriers, Agglate in the triple group was not
ignificantly higher than that in the high-MD group, but it
as numerically higher (Fig. 3A). Agglate after 5 mol/l
ADP stimulus was 22.8  15.6% versus 16.0  16.2% in
the triple versus high-MD group (p  0.144), whereas
Agglate after 20 mol/l ADP stimulus was 29.6  19.3%
ersus 22.6  19.6%, respectively (p  0.211). With regard
o carriers, the triple group showed greater values of
Agglate than the high-MD group (Fig. 3B): 24.6  15.4%
ersus 11.7  15.2% after 5 mol/l ADP stimulus
(p  0.001), and 28.1  19.4% versus 10.3  20.9% after
20 mol/l ADP stimulus (p 0.001). Regarding the rate of
PR in noncarriers, no group difference was seen at
re-discharge, but a numerically lower rate of 30-day HPR
as seen in the triple group (Fig. 4A, Table 3). Among
arriers, the pre-discharge rate of HPR was similar between
roups (Fig. 4B). However, the triple group demonstrated a
ignificantly lower rate of 30-day HPR than the high-MD
Table 3. Platelet Reactivity and Rate of HPR According to the CYP2C19 V
Noncarriers (n  49)
Variables
High-MD Group
(n  24)
Triple Group
(n  25)
Maximal platelet aggregation, %
20 mol/l ADP
Pre-discharge 54.1 16.1 58.4 11.9
30-day follow-up 38.6 12.0 37.5 13.2
5 mol/l ADP
Pre-discharge 42.4 15.7 46.9 11.8
30-day follow-up 30.1 10.1 28.2 11.5
Late platelet aggregation, %
20 mol/l ADP
Pre-discharge 44.4 22.7 49.4 15.7
30-day follow-up 21.8 14.8 19.7 16.8
5 mol/l ADP
Pre-discharge 32.5 18.2 36.4 13.5
30-day follow-up 16.4 9.2 13.6 11.7
VerifyNow P2Y12 assay
P2Y12 reaction unit
Pre-discharge 245.0 91.6 246.2 76.3
30-day follow-up 152.2 70.4 136.6 70.0
% inhibition
Pre-discharge 26.2 25.0 23.5 18.9
30-day follow-up 54.7 22.3 56.4 20.7
HPR
Pre-discharge 11 (45.8) 13 (52.0)
30-day follow-up 2 (8.3) 0 (0)
Values are mean SD or n (%).
ADP adenosine diphosphate; HPR high on-treatment platelet reactivity (20 mol/l ADP-indroup did. rPlatelet reactivity by the VerifyNow P2Y12 assay. At 30-day
follow-up, both treatments exhibited lower PRU and higher
percentage of inhibition compared with pre-discharge val-
ues irrespective of CYP2C19 genotype (all values;
p  0.001) (Table 3). In noncarriers, PRU did not
significantly differ among the regimens (109.6  63.1 vs.
92.8  60.7 in the triple vs. high-MD group, p  0.347)
(Fig. 5). However, triple antiplatelet therapy in carriers
showed a greater tendency toward an enhanced value of
PRU than high-MD clopidogrel did (91.1  85.0 vs.
57.3  69.4, p  0.060).
Comparison of treatment effect according to CYP2C19 genotype.
In the high-MD group, changes in 20 mol/l ADP-induced
latelet aggregation and PRU were greater for noncarriers than
or carriers, whereas 5 mol/l ADP-induced platelet aggrega-
ion in noncarriers showed a nonsignificant greater change
han carriers did (Table 4). The rate of 30-day HPR in
oncarriers was significantly lower than that in carriers. In the
riple group, changes in platelet measures in noncarriers were
imilar to those of carriers. In addition, triple antiplatelet
herapy could reduce sufficiently the rate of 30-day HPR
Carriage
Carriers (n  77)
p Value
High-MD Group
(n  38)
Triple Group
(n  39) p Value
0.293 60.0 15.2 59.2 14.4 0.802
0.752 52.3 17.5 35.0 19.3 0.001
0.256 46.6 16.7 46.6 15.6 0.995
0.547 37.6 16.0 24.9 14.3 0.001
0.379 50.9 21.7 51.6 17.7 0.878
0.649 40.6 22.2 23.5 19.2 0.001
0.397 38.4 20.7 39.8 17.4 0.749
0.347 26.7 16.5 15.2 12.4 0.001
0.959 241.6 79.3 263.0 72.5 0.220
0.441 184.2 80.6 171.9 86.3 0.518
0.672 22.0 19.2 21.1 16.8 0.825
0.783 40.3 23.5 48.0 24.0 0.157
0.666 20 (52.6) 24 (61.5) 0.430
0.235 17 (44.7) 6 (15.4) 0.005
aximal platelet aggregation59%); other abbreviations as in Table 1.ariantegardless of CYP2C19 genotype.
in Figu
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387Discussion
This platelet function study confirms the hypothesis that
adjunctive cilostazol to dual antiplatelet therapy in AMI
patients achieves adequate inhibition of ADP-induced platelet
aggregation regardless of CYP2C19 genotype. Conversely,
high-MD clopidogrel may show sufficient platelet inhibi-
tion in AMI patients without the CYP2C19 variant only
(19). Because East Asians have a higher prevalence of the
CYP2C19 LOF allele than whites do (60% vs. 30%)
Figure 2. Absolute Changes in Maximal Platelet Aggregation in Noncarrier
Absolute changes in maximal platelet aggregation in noncarriers (A) and carriers (
ADP  adenosine diphosphate; MD  maintenance-dose; other abbreviations as
Figure 3. Absolute Changes in Late Platelet Aggregation in Noncarriers an
Absolute changes in late platelet aggregation in noncarriers (A) and carriers (B
in Figures 1 and 2.(3–5), these findings might underlie the better clinical
outcomes in PCI-treated East Asians receiving triple anti-
platelet therapy compared with dual antiplatelet therapy
including standard- or double-dose clopidogrel.
Although PCI for AMI is considered standard manage-
ment, it may increase the interaction with enhanced platelet
reactivity and inflammation (20). Therefore, the PCI-based
approach for AMI needs potentiated inhibition of platelet
activation and inflammation for therapeutic success, espe-
cially in the early phase. Because the effect of clopidogrel is
Carriers of the CYP2C19 LOF Allele
the CYP2C19 loss-of-function (LOF) allele. Results are expressed as mean  SD.
re 1.
riers of the CYP2C19 LOF Allele
he CYP2C19 LOF allele. Results are expressed as mean  SD. Abbreviations ass and
B) ofd Car
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388modest, and potent P2Y12 inhibitors can reduce the risk of
post-PCI ischemic events in recent trials (21,22), greater
ADP-induced platelet inhibition is important to guarantee
Figure 4. Rate of HPR in Noncarriers and Carriers of the CYP2C19 LOF All
Rate of high on-treatment platelet reactivity (HPR) in noncarriers (A) and carrie
tivity (20 mol/l ADP-induced maximal platelet aggregation 59%). Abbreviat
Figure 5. Absolute Changes in PRU According to Carriage of the
CYP2C19 LOF Allele
Absolute changes in P2Y12 reaction unit (PRU) according to carriage of the
CYP2C19 LOF allele. Results are expressed as mean  SD. Abbreviations as
in Figures 1 and 2.a favorable prognosis in AMI patients. Many lines of
evidence demonstrate that insufficient formation of the
active metabolite is the primary explanation for clopidogrel
hyporesponsiveness. Although limited intestinal absorption
and functional variability in the CYP activity (drug-drug
interaction, genetic polymorphism, and so on) can reduce
the level of the active metabolite, recent studies have
documented the strong association between the CYP2C19
LOF variant carriage, and impaired platelet inhibition and
increased cardiovascular risk of AMI patients (3–5). Many
strategies to overcome the LOF effect of the CYP2C19
variants have garnered considerable attention. The present
study showed that a 150-mg MD of clopidogrel might not
achieve an adequate inhibitory effect in AMI carriers of the
CYP2C19 LOF variants, which might be related using the
same metabolic pathway. Platelet inhibition by adjunctive
cilostazol can be consistent irrespective of CYP2C19 geno-
type. Cilostazol is converted into 2 active metabolites,
namely OPC-13015 (dehydro-cilostazol) and OPC-13213
(monohydroxy-cilostazol) (11). OPC-13015 is generated
through the CYP3A4 pathway, whereas OPC-13213 is
generated by the CYP3A4/5 and CYP2C19 pathways. OPC-
13015 showed 9 times more potent inhibition compared
with platelet inhibition by OPC-13213. Therefore, the
platelet inhibitory effect by cilostazol mainly may be deter-
mined by the activity of the CYP3A4 pathway, which might
underlie the consistent ADP-induced platelet inhibition
seen regardless of CYP2C19 genotype with adjunctive
cilostazol in AMI patients.
Recent studies have suggested the possibility that higher
of the CYP2C19 LOF allele. HPR indicates high post-treatment platelet reac-
s in Figures 1 and 2.ele
rs (B)occupancy of platelet ADP P2Y12 receptor by ADP antag-
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389onists can increase the risk of bleeding (21–25), which
suggests that clinical efficacy of intensified platelet inhibi-
tion by potent antiplatelet regimens can translate into
reduced safety. We also must focus on the potential iden-
tification of a therapeutic window for P2Y12 receptor
lockade. Interestingly, there are no data for the increasing
isk of major or fatal bleeding by adjunctive cilostazol in
MI patients (7,8). Although there are no definite expla-
ations on this finding, some postulations have been sug-
ested. Cilostazol also improves endothelial function by
ncreased level of cyclic adenosine monophosphate (26).
ecause the process of bleeding may result from multiple
ross talks among the endothelium, platelets, and coagula-
ion factors, the cilostazol-activated endothelial cell might
ave an influence on the reduced risk of bleeding (27). In
ddition, cilostazol does not prolong bleeding time when
dded to aspirin or clopidogrel and has the reversible
roperty of platelet inhibition similar to ticagrelor (28).
ecause an East Asian population may have a relatively high
isk of disabling bleeding on treatment of the same strength
f oral anticoagulant and P2Y12 receptor blockade (29,30),
the routine introduction of intensified antiplatelet treatment
for high-risk subjects must be cautious. Given the clinical
and laboratory findings, adjunctive cilostazol might be a
favorable option if more potent P2Y12 inhibition is needed
for high-risk patients with predictable risks of bleeding.
Whereas the antiplatelet effect of the ticagrelor dose used
in the PLATO (Platelet Inhibition and Clinical Outcomes)
trial (21) closely matched that used for prasugrel in the
TRITON–Thrombolysis In Myocardial Infarction (Trial to
Assess Improvement in Therapeutic Outcomes by Optimiz-
ing Platelet Inhibition with Prasugrel–Thrombolysis In
Myocardial Infarction) trial (22), the magnitude and timing
of clinical benefit are entirely different between the 2
Table 4. Absolute Change in Platelet Reactivity and Rate of HPR Accordin
High-MD Group (n  62)
Variables
Noncarriers
(n  24)
Carriers
(n  38)
Absolute change in maximal
platelet aggregation, %
20 mol/l ADP 15.5 15.1 7.7 15.5
5 mol/l ADP 12.3 13.8 9.0 13.3
Absolute change in late
platelet aggregation, %
20 mol/l ADP 22.6 19.6 10.3 20.9
5 mol/l ADP 16.0 16.2 11.7 15.2
Absolute change in P2Y12
reaction unit
92.8 60.7 57.3 69.4
HPR at 30-day follow-up 2 (8.3) 17 (44.7)
Values are mean SD or n (%).
Abbreviations as in Tables 1 and 3.regimens in patients with acute coronary syndrome (31).Compared with clopidogrel, remarkable reductions of vas-
cular death and AMI by ticagrelor cannot be explained by
only enhanced platelet inhibition. Favorable clinical out-
comes in patients treated with ticagrelor might be explained
by the up-regulation of adenosine receptors (31). In addi-
tion to causing reversible platelet inhibition, adenosine is
involved in numerous biological activities including cardio-
protection from reperfusion injury, apoptosis, myocyte
regeneration, improved myocardial contractility, and elec-
trical stability. Likewise, recent studies also have shown the
pleiotropic effect of cilostazol on the atherothrombotic
milieu. Cilostazol increases the level of adenosine (27),
protects the cardiac cells from ischemia-reperfusion injury
(32), restores endothelial dysfunction (26), inhibits inflam-
mation and oxidative stress (33), and reduces neointima
hyperplasia after coronary stenting (34). Therefore, poten-
tial mechanisms contributing to the benefits of adjunctive
cilostazol might include not only consistent platelet inhibi-
tion, but also other pleiotropic effects beyond pure P2Y12
receptor inhibition.
Two recent, large prospective studies have addressed the
modest clinical benefit of doubling LD or MD of clopi-
dogrel in patients with acute coronary syndrome or under-
going nonemergent PCI, which may be mainly associated
with inadequate platelet inhibition by doubling clopidogrel
dose in some patients (23,35). One of most important risk
factors for HPR was the carriage of CYP2C19 LOF allele in
patients treated with 600-mg LD or 150-mg/day MD
clopidogrel (19,36). Although a repeated 600-mg extra
loading-dose appears to overcome the LOF effect of
CYP2C19 variant (36), this kind of tailoring of antiplatelet
therapy may be somewhat difficult to adapt in clinical
practice. Antiplatelet response of new potent P2Y12 inhib-
itors has not been related with the status of CYP2C19
reatment Regimen
Triple Group (n  64)
p Value
Noncarriers
(n  25)
Carriers
(n  39) p Value
0.056 20.9 13.9 24.2 17.2 0.428
0.354 18.8 12.5 21.8 13.9 0.387
0.025 29.6 19.3 28.1 19.4 0.758
0.289 22.8 15.6 24.6 15.4 0.648
0.044 109.6 63.1 91.1 85.0 0.355
0.002 0 (0) 6 (15.4) 0.174g to Tgenotyping, which can be a promising alternative to surpass
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390the limitation of clopidogrel (21,22). The CILON-T (influ-
nce of CILostazol-based triple antiplatelet therapy ON
schemic complication after drug-eluting stenT implanta-
ion) trial (37) showed no benefit of adjunctive cilostazol in
CI-treated patients. The CILON-T trial did not assess
he beneficial role of cilostazol during PCI and included
elatively low-risk patients. Approximately 10% of the total
ohort (n  960) showed elevated cardiac enzyme, and
-month composite of cardiac death, nonfatal MI, and
schemic stroke was much lower (2.0%). Contrary to
revious studies, the beneficial influence of cilostazol on
estenosis did not appear. A large-scale study that includes
igh-risk patients is required to assess the role of adjunctive
ilostazol in post-PCI short- and long-term clinical events.
Study limitations. First, the follow-up period was short and
he number of patients studied was small. Second, the
resent study included East Asian patients using only
aboratory data. Third, the time point of pre-discharge
latelet measures might be another limitation. Matetzky et
l. (1) showed that there might be no significant changes of
ost-clopidogrel platelet reactivity from days 3 to 5 after
CI in AMI patients. Because we assessed platelet reactivity
rom 3 to 5 days after PCI, the results principally reflect
re-discharge residual platelet reactivity. However, pre-
ischarge values of platelet reactivity were not different
etween carriers and noncarriers, which may be reflective of
nherent exaggerated variability in platelet reactivity of AMI
atients. Fourth, the rate of the side effects after cilostazol
se seems somewhat low, which may indicate the compli-
nce of medication. However, we double-checked the pa-
ients’ side effects using a questionnaire and verbal commu-
ication. Inter-racial difference, the duration of the study,
nd the features of enrolled patients may explain this
iscrepancy. Finally, the degree of absolute change in
latelet measures was influenced by the ADP concentration.
ecause low ADP concentrations can sometimes cause
rimary aggregation only, it may artificially blunt the drug
ffect. In the present study, PRU and LTA by a high
oncentration of ADP also used 20 mol/l ADP, which
ay be more representative of the high thrombogenic
onditions of AMI (38).
onclusions
Among PCI-treated AMI patients, adjunctive cilostazol
may enhance platelet inhibition and reduce the rate of HPR
without the influence of the CYP2C19 LOF variant alleles,
whereas high-MD clopidogrel may be affected by the
CYP2C19 LOF variant carriage.
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